Summary & Overview
HCPCS J9307: Injection, Pralatrexate, 1 mg
HCPCS Level II code J9307 designates the injection of pralatrexate, dosed per 1 mg units, and is used to bill for administration of this oncology drug in outpatient infusion settings. Pralatrexate is an antineoplastic agent prescribed for certain hematologic malignancies, and accurate coding is essential for coverage determination, clinical documentation, and payment processing at a national level. The code matters nationally because specialty drug billing affects payer reimbursement policies, prior authorization workflows, and site-of-service cost differences.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J9307 is used clinically, typical sites of service where the drug is administered, and the scope of payer engagement. The publication summarizes benchmarks and coverage patterns where available, highlights relevant policy updates affecting specialty oncology drug billing, and provides clinical context for service-line stakeholders managing infusion therapy. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9307 represents the injection of pralatrexate, 1 mg. This billing code is used to report administration of the antineoplastic agent pralatrexate, typically delivered as an injectable formulation for oncology treatment.
Service Type: Injection / Drug administration
Typical Site of Service: Outpatient infusion center or hospital outpatient department, where chemotherapy and specialty oncology injections are commonly administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with relapsed or refractory peripheral T‑cell lymphoma presents to the outpatient oncology infusion clinic for administration of pralatrexate. The oncologist prescribes intravenous chemotherapy using J9307 (injection, pralatrexate, 1 mg) dosed per body surface area. Prior to infusion, the clinic completes pre‑infusion vitals, recent laboratory review (CBC, CMP, liver function tests), medication reconciliation, and verifies prior authorization and drug eligibility with payors including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare. A certified oncology nurse performs IV access placement, documents chemotherapy consent and toxicity counseling, prepares the dose in pharmacy under sterile technique, and records lot number and expiration for inventory control. During infusion the nurse monitors for adverse reactions; post‑infusion monitoring and supportive care (antiemetics, hydration) are documented. Billing uses J9307 units corresponding to milligrams administered; applicable modifiers are appended based on circumstances (facility vs professional, drug wastage, patient status, and payer requirements). Clinical notes include diagnosis code(s) for the hematologic malignancy, weight/BSA, chemotherapy regimen cycle number, and administration details to support the J‑code billing and medical necessity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |